Core Insights - The company reported a revenue of 1.358 billion yuan for the first three quarters of 2025, marking a year-on-year growth of 10.59% [1] - The net profit attributable to shareholders reached 86.839 million yuan, with a year-on-year increase of 5.2% [1] - The non-recurring net profit attributable to shareholders was 85.431 million yuan, reflecting a year-on-year growth of 12.53% [1] Financial Performance - The operating cash flow has shown continuous improvement throughout the year, with net cash flow from operating activities reaching 68.68 million yuan in Q1, 79.94 million yuan in Q2 (a quarter-on-quarter growth of over 16.4%), and 99.11 million yuan in Q3 (a quarter-on-quarter growth of 23.97%) [1] - The stable cash flow provides a solid financial foundation for the company's future development [1] Strategic Focus - The integration of "Healthcare + AI" is a core strategy for the company, driving high-quality development [2] - The company aims to reshape the entire medical service chain through AI, enhancing capabilities, efficiency, and patient experience [2] - The company is positioned favorably in the healthcare industry, leveraging AI technology to maintain profitability and growth amid increasing differentiation in the private healthcare sector [2]

Group 1 - The core point of the article is that Yingkang Life (SZ 300143) held a temporary board meeting on October 27, 2025, to discuss the revision of the internal audit system [1] - For the first half of 2025, Yingkang Life's revenue composition was 77.47% from medical services and 22.53% from health care [1] - As of the report date, Yingkang Life's market capitalization was 8.1 billion yuan [1]

北京商报讯（记者 王寅浩 宋雨盈）10月27日，盈康生命发布2025年第三季度报告，第三季度实现营业 收入5.15亿元，同比增长27.27%；归属于上市公司股东的净利润为2501.17万元，同比下降9.85%。2025 年前三季度实现营业收入13.58亿元，同比增长10.59%；归属于上市公司股东的净利润为8683.89万元， 同比增长5.2%。 ...

盈康生命科技股份有限公司 盈康生命科技股份有限公司 内部审计制度 （2025年10月） 第一章 总则 第一条 为加强盈康生命科技股份有限公司（以下简称"本公司"或"公司"）内 部监督和风险控制,保障公司财务管理、会计核算和生产经营符合国家各项法律法 规要求，维护包括中小投资者的所有股东的合法权益，根据《中华人民共和国公司 法》（以下简称"《公司法》"）、《中华人民共和国证券法》、《中华人民共和国审计法》、 《审计署关于内部审计工作的规定》、《深圳证券交易所上市公司自律监管指引第2 号—创业板上市公司规范运作》等法律、法规、规范性文件及《盈康生命科技股份有 限公司章程》（以下简称"公司章程"）的有关规定，结合本公司的实际情况，制定 本制度。 第二条 内部审计是指由公司内部机构或人员，对其内部控制和风险管理的有 效性、财务信息的真实性和完整性以及经营活动的效率和效果等开展的一种评价活动。 公司依法实行内部审计制度，确保公司的各项行为符合国家法律、法规、规章 及其他相关规定的要求；合理保证财务及非财务信息报告的真实、完整、可靠，提 高信息报告的质量；保障公司资产安全、完整；有效控制成本，改善经营管理，提 高经营效率 ...

证券代码：300143 证券简称：盈康生命 公告编号：2025-043 盈康生命科技股份有限公司 第六届董事会第二十一次（临时）会议决议公告 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 盈康生命科技股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日以电话、 邮件等方式向全体董事发出召开公司第六届董事会第二十一次（临时）会议的通知。 会议于 2025 年 10 月 27 日在山东省青岛市崂山区海尔路一号盈康一生大厦董事会议 室以现场结合通讯的方式召开。会议应出席董事 9 人，实际出席董事 9 人，董事谭 丽霞、马安捷以现场方式出席会议并投票表决，董事黄雯瑶、龚雯雯、潘绵顺、沈 旭东、独立董事杜媛、独立董事姜峰、独立董事陈晓满以通讯方式出席会议并投票 表决。本次会议由董事长谭丽霞女士主持，公司的高级管理人员列席了会议。 本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》《公 司章程》及有关法律、法规的规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 年第三季度报告的议案》 董事会审议 ...

Revenue and Profitability - The company's revenue for Q3 2025 reached ¥514,808,385, representing a 27.27% increase compared to ¥404,486,660 in the same period last year[4]. - Net profit attributable to shareholders was ¥25,011,711, a decrease of 9.85% from ¥27,743,511 in the previous year[4]. - Basic earnings per share decreased by 23.29% to ¥0.0336 from ¥0.0438 in the same period last year[5]. - Total operating revenue for the current period reached ¥1,357,762,551.29, an increase of 10.6% compared to ¥1,227,709,136.74 in the previous period[29]. - Net profit for the current period was ¥93,807,045.54, representing a 12.5% increase from ¥83,199,781.04 in the previous period[30]. - Earnings per share (EPS) for the current period was ¥0.1168, compared to ¥0.1298 in the previous period, indicating a decrease of 8.2%[31]. - The total comprehensive income for the current period was ¥93,895,819.28, compared to ¥83,135,409.36 in the previous period, indicating a growth of 12.5%[31]. Assets and Liabilities - Total assets increased by 20.37% to ¥4,257,327,588.46 from ¥3,536,733,888.57 at the end of the previous year[5]. - The company reported a total asset of CNY 4,257,327,588.46 as of September 30, 2025, an increase from CNY 3,536,733,888.57 at the beginning of the period[25]. - The company’s total liabilities amounted to CNY 1,835,286,010.02, up from CNY 1,774,670,349.86, reflecting an increase of about 3.2%[26]. - Total liabilities increased to ¥1,640,439,218.11 from ¥1,058,411,535.22, marking a rise of 55%[27]. - Current liabilities due within one year increased by 179.11% to ¥71,898,137.89, primarily due to the leasing of the Guangci Phase II building[12]. - Long-term borrowings rose by 205.44% to ¥466,107,484.50, mainly attributed to increased acquisition loans[12]. Cash Flow and Investments - The company’s cash flow from operating activities showed a slight increase of 0.33% to ¥247,729,500 from ¥246,904,100[5]. - Cash generated from operating activities was ¥1,404,151,215.96, compared to ¥1,281,039,988.86 in the previous period, reflecting a growth of 9.6%[32]. - Total cash inflow from investment activities was $522.90 million, significantly higher than $275.19 million in the prior period, representing an increase of 90.00%[33]. - Cash outflow from investment activities totaled $1.12 billion, up from $699.19 million, indicating a rise of 60.00%[33]. - Net cash flow from financing activities was $184.85 million, compared to $58.36 million in the previous period, showing an increase of 216.00%[33]. - Cash received from investments was $522.81 million, a notable increase from $271.99 million, representing a growth of 92.00%[33]. Equity and Shareholder Information - The company’s total equity attributable to shareholders rose by 3.87% to ¥2,524,691,985.61 from ¥2,430,580,107.07[5]. - Minority interests increased by 93.11% to ¥92,196,384.74, primarily due to the consolidation of Changsha Kexin[12]. - The company had a total of 19,839 common shareholders at the end of the reporting period[14]. - The largest shareholder, Qingdao Yinkang Medical Investment Co., Ltd., holds 49.61% of the shares, totaling 371,782,549 shares[14]. Expenses and Taxation - Total operating costs amounted to ¥1,224,176,374.67, up from ¥1,121,158,642.67, reflecting a growth of 9.2%[29]. - Total tax and additional charges increased by 44.63% to ¥3,934,951.01, primarily due to higher stamp duty and property tax[12]. - Financial expenses rose by 85.13% to ¥4,822,293.98, mainly due to increased long-term borrowings[12]. - Research and development expenses for the current period were ¥32,062,692.84, a decrease of 13% from ¥36,844,629.34 in the previous period[30]. Goodwill and Other Assets - Goodwill increased by 45.91% to ¥1,011,564,085.90 due to the acquisition of Changsha Kexin[11]. - The company’s goodwill rose significantly to CNY 1,011,564,085.90 from CNY 693,292,987.91, indicating an increase of about 45.8%[26]. - The company experienced a 201.83% increase in other receivables, reaching ¥117,456,775.68 from ¥38,914,515.15[11]. Financial Condition and Future Outlook - The company’s financial condition is expected to improve following the approval of the plan to use surplus reserves to cover losses, which is aimed at enhancing investor returns and protecting the rights of minority shareholders[19]. - The company plans to use CNY 1,457,808,920.00 from its surplus reserves and capital reserves to offset accumulated losses, which will reduce surplus reserves to CNY 0[20][21].

Core Insights - The "Mushroom Power Planet" agricultural product promotion event in Shaoguan successfully integrated local culture and tourism, attracting nearly 10,000 participants offline and generating over 50 million online exposures [1][2][4] - The event utilized a live-streaming sales model, significantly enhancing consumer engagement and driving sales through platforms like TVB, which attracted nearly 3 million online viewers [2][3] - The launch of the "Shaozhou Good Scenery" platform aims to create a sustainable online sales channel for local products, promoting year-round purchasing habits among consumers [3][4] Group 1 - The event showcased over 60% of Guangdong's edible mushroom production, emphasizing the region's agricultural strength [1] - The integration of local cultural elements, such as Cantonese food discussions and traditional performances, enhanced audience interaction and experience [2][3] - The event's innovative approach transformed traditional agricultural marketing by creating immersive experiences that combined food tasting, cultural performances, and direct interaction with celebrities [3] Group 2 - The collaboration with Hong Kong TVB for live streaming significantly amplified the event's reach and sales impact, demonstrating the effectiveness of media partnerships in agricultural promotion [2][3] - The event highlighted the modernized industrial chain of Shaoguan's edible mushroom sector, showcasing advancements from research to production [3] - The focus on agricultural and cultural integration not only boosted local product visibility but also stimulated the tourism market, positioning Shaoguan's regional brands prominently [4]

Core Viewpoint - Yingkang Life (300143) reported that as of September 30, 2025, the total number of shareholders is 19,839 [1] Summary by Category - **Company Information** - Yingkang Life has a total of 19,839 shareholders as of the specified date [1]

Core Viewpoint - Yingkang Life's stock price increased by 1.78% on September 30, with a trading volume of 124 million yuan, indicating positive market sentiment towards the company [1]. Financing Summary - On September 30, Yingkang Life had a financing buy-in amount of 13.63 million yuan and a financing repayment of 27.28 million yuan, resulting in a net financing outflow of 13.65 million yuan [1]. - As of September 30, the total financing and securities lending balance for Yingkang Life was 269 million yuan, which accounts for 3.67% of its market capitalization, indicating a high level of financing activity compared to the past year [1]. - The company had a securities lending repayment of 16,800 shares and a securities lending sell-out of 200 shares, with a sell-out amount of 2,284 yuan, reflecting low securities lending activity [1]. Company Overview - Yingkang Life Technology Co., Ltd. is located in Qingdao, Shandong Province, and was established on August 6, 1998, with its listing date on December 9, 2010 [2]. - The company's main business involves medical devices and medical services, with a focus on developing, producing, and selling advanced radiation therapy equipment and establishing a specialized cancer treatment service network [2]. - The revenue composition of Yingkang Life includes 77.47% from medical services and 22.53% from medical devices and consumables [2]. Financial Performance - For the first half of 2025, Yingkang Life reported a revenue of 843 million yuan, representing a year-on-year growth of 2.40%, and a net profit attributable to shareholders of 61.83 million yuan, which is a 12.82% increase compared to the previous year [2]. Dividend Information - Since its A-share listing, Yingkang Life has distributed a total of 29.48 million yuan in dividends, with no dividends paid in the last three years [3].

Group 1 - The core viewpoint of the news is that Yingkang Life has shown a positive stock performance with a year-to-date increase of 24.46% and a recent price of 11.45 CNY per share, despite some fluctuations in trading volume and net capital outflow [1] - As of September 19, the number of shareholders for Yingkang Life decreased by 16.28% to 20,500, while the average circulating shares per person increased by 19.45% to 31,286 shares [2] - The company reported a revenue of 843 million CNY for the first half of 2025, reflecting a year-on-year growth of 2.40%, and a net profit attributable to shareholders of 61.83 million CNY, which is a 12.82% increase year-on-year [2] Group 2 - Yingkang Life specializes in medical devices and services, focusing on cancer prevention, diagnosis, treatment, and rehabilitation, with a revenue composition of 77.47% from medical services and 22.53% from medical devices and consumables [2] - The company has cumulatively distributed 29.48 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]